Tenderwize
Wróć do wyszukiwania

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Mar 30, 2027 · 219 days left·Open·Supplies
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Arzneimittel mit der Wirkstoffkombination Cinnarizin und Dimenhydrinat (ATC: N07CA22)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)
  • Conclusion of non-exclusive discount agreements under §130a Abs. 8 SGB V
Pokaż pełne podsumowanie

This notice announces a non-exclusive discount agreement (Rabattvertrag) under §130a Abs. 8 SGB V for finished medicinal products containing the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22). It follows an open-house model, allowing any qualified pharmaceutical company to conclude a standard contract at any time. The contract runs for a maximum of 24 months from the earliest start date (01.06.2025) until 31.05.2027. The notice explicitly states it is not a public procurement under GWB but is published for transparency. No estimated value or framework maximum value is provided. The submission process is unclear: structured data indicates electronic submission is not allowed, but the XML notice mentions the possibility of submitting electronically signed documents via email.

Ryzyka

No estimated value or framework maximum is provided, making it impossible to assess potential revenue. The contract is...

The buyer explicitly reserves the right to terminate the agreement if exclusive contracts for the same active ingredien...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies
  • Contract must be signed and returned to the contact address

Administrative

  • Must request and submit participation documents fully completed and signed

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

Magdeburg, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE258393558

Działalność

Health

Części (1)

LOT-0001

Medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22)

Non-exclusive discount agreements for finished medicinal products with the active ingredient combination cinnarizine and dimenhydrinate (ATC: N07CA22) under an open-house model. Any qualified pharmaceutical company can join at any time. No exclusivity. Contract duration: maximum 24 months, ending 31.05.2027 irrespective of start date. Early termination possible if the health insurance fund (AOK Sachsen-Anhalt) tenders exclusive contracts during the term.

SuppliesEU fundedElectronic submission

Lokalizacja

DEE03, Germany

Czas trwania

2 YEAR

Kategoria

Pharmaceutical products

Termin

Deadline Mar 30, 2027

Szczegóły zamówienia

Data publikacji
09 Apr 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
234181-2025

Dokumenty (1)

Podobne przetargi